Ludwig Kappos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9180474/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risk of requiring a walking aid after 6.5Âyears of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials. European Journal of Neurology, 2022, 29, 1238-1242.	3.3	9
2	Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. European Journal of Neurology, 2022, 29, 1082-1090.	3.3	11
3	Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS. Multiple Sclerosis Journal, 2022, 28, 573-582.	3.0	17
4	Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients. Cerebellum, 2022, 21, 632-646.	2.5	8
5	Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. Multiple Sclerosis Journal, 2022, 28, 801-816.	3.0	26
6	Microstructure-Weighted Connectomics in Multiple Sclerosis. Brain Connectivity, 2022, 12, 6-17.	1.7	4
7	Body mass index as a predictor of MS activity and progression among participants in BENEFIT. Multiple Sclerosis Journal, 2022, 28, 1277-1285.	3.0	12
8	Spinal cord gray matter atrophy is associated with functional decline in postâ€ p olio syndrome. European Journal of Neurology, 2022, 29, 1435-1445.	3.3	6
9	Bundle myelin fraction (BMF) mapping of different white matter connections using microstructure informed tractography. NeuroImage, 2022, 249, 118922.	4.2	15
10	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	3.0	16
11	Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	32
12	Multiple Sclerosis Relapses Following Cessation of Fingolimod. Clinical Drug Investigation, 2022, 42, 355-364.	2.2	8
13	Immunological Predictors of Dimethyl Fumarateâ€Induced Lymphopenia. Annals of Neurology, 2022, 91, 676-681.	5.3	8
14	Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Frontiers in Immunology, 2022, 13, 852563.	4.8	18
15	Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Multiple Sclerosis Journal, 2022, 28, 1576-1590.	3.0	24
16	Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies. Frontiers in Neurology, 2022, 13, 809273.	2.4	2
17	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurology, The, 2022, 21, 246-257.	10.2	210
18	Changes in the Cerebrospinal Fluid and Plasma Lipidome in Patients with Rett Syndrome. Metabolites, 2022, 12, 291.	2.9	14

#	Article	IF	CITATIONS
19	Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Multiple Sclerosis Journal, 2022, 28, 1562-1575.	3.0	25
20	Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. Multiple Sclerosis Journal, 2022, 28, 1526-1540.	3.0	16
21	Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS. Annals of Neurology, 2022, 91, 814-820.	5.3	7
22	Blood Neurofilament Light in Progressive Multiple Sclerosis. Neurology, 2022, 98, .	1.1	18
23	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Multiple Sclerosis Journal, 2022, , 135245852210845.	3.0	2
24	Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years. Multiple Sclerosis Journal, 2022, 28, 1591-1605.	3.0	19
25	Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon betaâ€1a. European Journal of Neurology, 2022, 29, 2024-2035.	3.3	6
26	Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies. Multiple Sclerosis Journal, 2022, 28, 1719-1728.	3.0	8
27	Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. JAMA Neurology, 2022, 79, 682.	9.0	41
28	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 2022, , .	3.3	1
29	021†Determinants of natalizumab-associated PML outcomes. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A20.1-A20.	1.9	0
30	034†Updated safety analysis of ocrelizumab in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A24.1-A24.	1.9	0
31	Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of Neurology, 2022, 269, 5093-5104.	3.6	7
32	023†Relapse outcomes with natalizumab Q4W vs switch to Q6W. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A20.3-A21.	1.9	0
33	018†Disease control beyond NEDA: the value of non-clinical measures to determine treatment response to natalizumab. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A19.1-A19.	1.9	Ο
34	116†Serum immunoglobulin levels and infection risk in Phase 3 ofatumumab trials in relapsing multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A137.2-A137.	1.9	0
35	020†Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A19.3-A20.	1.9	0
36	A New Advanced <scp>MRI</scp> Biomarker for Remyelinated Lesions in Multiple Sclerosis. Annals of Neurology, 2022, 92, 486-502.	5.3	28

#	Article	IF	CITATIONS
37	Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. Multiple Sclerosis Journal, 2022, 28, 1927-1936.	3.0	10
38	Improving Detection of Change in Motor Functioning in Multiple Sclerosis Using Video-Assisted Composite Measures. International Journal of MS Care, 2022, , .	1.0	0
39	Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial. Multiple Sclerosis Journal, 2022, 28, 1944-1962.	3.0	16
40	Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1564-1576.	3.0	16
41	Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate. Multiple Sclerosis Journal, 2021, 27, 439-448.	3.0	8
42	Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri [®] Observational Program (TOP). Multiple Sclerosis Journal, 2021, 27, 410-419.	3.0	7
43	The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. Multiple Sclerosis Journal, 2021, 27, 479-482.	3.0	7
44	Real-world disability improvement in patients with relapsing–remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. Multiple Sclerosis Journal, 2021, 27, 719-728.	3.0	15
45	Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis. Journal of Neurology, 2021, 268, 941-949.	3.6	16
46	Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	3
47	Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. British Journal of Clinical Pharmacology, 2021, 87, 2511-2520.	2.4	39
48	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Multiple Sclerosis and Related Disorders, 2021, 48, 102673.	2.0	20
49	Biomarkers of treatment response in patients with progressive multiple sclerosis treated with highâ€dose pharmaceuticalâ€grade biotin (MD1003). Brain and Behavior, 2021, 11, e01998.	2.2	3
50	Serum neurofilament light chain as outcome marker for intensive care unit patients. Journal of Neurology, 2021, 268, 1323-1329.	3.6	11
51	Standardization and digitization of clinical data in multiple sclerosis. Nature Reviews Neurology, 2021, 17, 119-125.	10.1	8
52	Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. Annals of Neurology, 2021, 89, 610-616.	5.3	68
53	Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references. NeuroImage: Clinical, 2021, 30, 102659.	2.7	3
54	Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	21

#	Article	IF	CITATIONS
55	Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642098794.	3.5	4
56	Classification of multiple sclerosis based on patterns of <scp>CNS</scp> regional atrophy covariance. Human Brain Mapping, 2021, 42, 2399-2415.	3.6	10
57	Impact of complement activation on clinical outcomes in multiple sclerosis. Annals of Clinical and Translational Neurology, 2021, 8, 944-950.	3.7	4
58	Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2219-2231.	3.0	7
59	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective. JAMA Neurology, 2021, 78, 351.	9.0	30
60	Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging. Brain, 2021, 144, 1684-1696.	7.6	61
61	GAMER-MRI in Multiple Sclerosis Identifies the Diffusion-Based Microstructural Measures That Are Most Sensitive to Focal Damage: A Deep-Learning-Based Analysis and Clinico-Biological Validation. Frontiers in Neuroscience, 2021, 15, 647535.	2.8	4
62	MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a. Multiple Sclerosis and Related Disorders, 2021, 49, 102790.	2.0	8
63	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. Journal of Neurology, 2021, 268, 3961-3968.	3.6	47
64	Artificial intelligence extension of the OSCARâ€ŀB criteria. Annals of Clinical and Translational Neurology, 2021, 8, 1528-1542.	3.7	33
65	Practice Effects of Mobile Tests of Cognition, Dexterity, and Mobility on Patients With Multiple Sclerosis: Data Analysis of a Smartphone-Based Observational Study. Journal of Medical Internet Research, 2021, 23, e30394.	4.3	21
66	Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study. JAMA Neurology, 2021, 78, 558.	9.0	132
67	Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis. Brain, 2021, 144, 1296-1311.	7.6	81
68	Syndrome of inappropriate antidiuretic hormone secretion and hypothalamic hypocortisolism in neuromyelitis optica. Lancet, The, 2021, 397, 2194.	13.7	1
69	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. Multiple Sclerosis and Related Disorders, 2021, 51, 102844.	2.0	19
70	Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. Annals of Neurology, 2021, 90, 477-489.	5.3	16
71	Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis. Neurology, 2021, 97, e543-e553.	1.1	54
72	Death Anxiety and Attitudes towards Death in Patients with Multiple Sclerosis: An Exploratory Study. Brain Sciences, 2021, 11, 964.	2.3	6

#	Article	IF	CITATIONS
73	Imaging multiple sclerosis pathology at 160Âμm isotropic resolution by human whole-brain ex vivo magnetic resonance imaging at 3AT. Scientific Reports, 2021, 11, 15491.	3.3	5
74	Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsingâ€remitting multiple sclerosis. European Journal of Neurology, 2021, 28, 4135-4145.	3.3	13
75	Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer. Frontiers in Neurology, 2021, 12, 693333.	2.4	8
76	067â€Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials. , 2021, , .		0
77	No consensus about consensus?. Neurological Research and Practice, 2021, 3, 46.	2.0	4
78	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. European Journal of Neurology, 2021, 28, 3722-3730.	3.3	12
79	2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurology, The, 2021, 20, 653-670.	10.2	302
80	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. Computer Methods and Programs in Biomedicine, 2021, 208, 106180.	4.7	21
81	Central nervous system atrophy predicts future dynamics of disability progression in a realâ€world multiple sclerosis cohort. European Journal of Neurology, 2021, 28, 4153-4166.	3.3	10
82	Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. Neurology, 2021, 97, e1546-e1559.	1.1	75
83	GAMER MRI: Gated-attention mechanism ranking of multi-contrast MRI in brain pathology. NeuroImage: Clinical, 2021, 29, 102522.	2.7	4
84	Fingolimod in children with Rett syndrome: the FINGORETT study. Orphanet Journal of Rare Diseases, 2021, 16, 19.	2.7	12
85	No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110424.	3.5	9
86	Siponimod and Cognition in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 96, e376-e386.	1.1	64
87	Measuring treatment response to advance precision medicine for multiple sclerosis. Annals of Clinical and Translational Neurology, 2021, 8, 2166-2173.	3.7	6
88	Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis. Diagnostic and Prognostic Research, 2021, 5, 17.	1.8	4
89	Additive and interaction effects of working memory and motor sequence training on brain functional connectivity. Scientific Reports, 2021, 11, 23089.	3.3	4
90	Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 1001-1011.	10.2	36

#	Article	IF	CITATIONS
91	Setwise comparison: efficient fine-grained rating of movement videos using algorithmic support – a proof of concept study. Disability and Rehabilitation, 2020, 42, 2640-2646.	1.8	2
92	Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials. Multiple Sclerosis Journal, 2020, 26, 993-996.	3.0	6
93	Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide. Multiple Sclerosis Journal, 2020, 26, 1207-1216.	3.0	23
94	New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis. Journal of Neurology, 2020, 267, 192-202.	3.6	12
95	Short timescale modulation of cortical and cerebellar activity in the early phase of motor sequence learning: an fMRI study. Brain Imaging and Behavior, 2020, 14, 2159-2175.	2.1	6
96	Neurofilament light levels are associated with long-term outcomes in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1691-1699.	3.0	67
97	No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon β-1a. Multiple Sclerosis and Related Disorders, 2020, 39, 101891.	2.0	4
98	Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis and Related Disorders, 2020, 39, 101865.	2.0	5
99	Video-Based Pairwise Comparison: Enabling the Development of Automated Rating of Motor Dysfunction in Multiple Sclerosis. Archives of Physical Medicine and Rehabilitation, 2020, 101, 234-241.	0.9	7
100	Evolution of Cortical and White Matter Lesion Load in Early-Stage Multiple Sclerosis: Correlation With Neuroaxonal Damage and Clinical Changes. Frontiers in Neurology, 2020, 11, 973.	2.4	8
101	Muscle stiffness, gait instability, and liver cirrhosis in Wilson's disease. Lancet, The, 2020, 396, 990.	13.7	0
102	Five years of ocrelizumab in relapsing multiple sclerosis. Neurology, 2020, 95, e1854-e1867.	1.1	81
103	Laminar analysis of the cerebellar cortex shows widespread damage in early MS patients: A pilot study at 7T MRI. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732096140.	1.0	1
104	Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine, 2020, 383, 546-557.	27.0	358
105	Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study. Multiple Sclerosis and Related Disorders, 2020, 46, 102438.	2.0	14
106	Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 998-1009.	10.2	98
107	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756.	7.6	24
108	Long-term prognostic value of longitudinal measurements of blood neurofilament levels. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	27

#	Article	IF	CITATIONS
109	Improving Accuracy of Brainstem MRI Volumetry: Effects of Age and Sex, and Normalization Strategies. Frontiers in Neuroscience, 2020, 14, 609422.	2.8	0
110	Levels of brainâ€derived neurotrophic factor in patients with multiple sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 2251-2261.	3.7	23
111	Xenogeneic Neu5Gc and self-glycan Neu5Ac epitopes are potential immune targets in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	6
112	Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642091500.	3.5	47
113	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. Neurology, 2020, 94, e2457-e2467.	1.1	61
114	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Multiple Sclerosis Journal, 2020, 26, 1031-1044.	3.0	39
115	Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurology, 2020, 77, 1132.	9.0	245
116	White matter lesion location correlates with disability in relapsing multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732090684.	1.0	5
117	Efficacy of inpatient personalized multidisciplinary rehabilitation in multiple sclerosis: behavioural and functional imaging results. Journal of Neurology, 2020, 267, 1744-1753.	3.6	5
118	Growth differentiation factor 15 is increased in stable MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	12
119	Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort. Journal of Neurology, 2020, 267, 3541-3554.	3.6	14
120	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nature Reviews Neurology, 2020, 16, 171-182.	10.1	150
121	Longitudinal patterns of cortical thinning in multiple sclerosis. Human Brain Mapping, 2020, 41, 2198-2215.	3.6	26
122	Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis. Journal of Neurology, 2020, 267, 1536-1546.	3.6	35
123	Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurology, The, 2020, 19, 336-347.	10.2	90
124	Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology, 2020, 94, e1201-e1212.	1.1	88
125	Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 660-668.	1.9	97
126	The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732090795.	1.0	4

#	Article	IF	CITATIONS
127	Vitamin D, smoking, EBV, and long-term cognitive performance in MS. Neurology, 2020, 94, e1950-e1960.	1.1	45
128	Monitoring of radiologic disease activity by serum neurofilaments in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	24
129	Autoencoder as a New Method for Maintaining Data Privacy While Analyzing Videos of Patients With Motor Dysfunction: Proof-of-Concept Study. Journal of Medical Internet Research, 2020, 22, e16669.	4.3	2
130	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Multiple Sclerosis Journal, 2019, 25, 1255-1262.	3.0	37
131	Preferential spinal cord volume loss in primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 947-957.	3.0	44
132	Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. JAMA Neurology, 2019, 76, 1359.	9.0	129
133	Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. JAMA Neurology, 2019, 76, 1446.	9.0	119
134	Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641987832.	3.5	54
135	Automatic Spinal Cord Gray Matter Quantification: A Novel Approach. American Journal of Neuroradiology, 2019, 40, 1592-1600.	2.4	10
136	PML with dimethyl fumarate—No convincing case against natalizumab. Multiple Sclerosis Journal, 2019, 25, 1687-1688.	3.0	1
137	Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain, 2019, 142, 2787-2799.	7.6	136
138	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1009-1020.	10.2	191
139	Hereditary defect of cobalamin metabolism with adolescence onset resembling multiple sclerosis: 41-year follow up in two cases. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641987211.	3.5	3
140	Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology, 2019, 93, e1778-e1786.	1.1	37
141	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1021-1033.	10.2	184
142	Clinical associations of T2-weighted lesion load and lesion location in small vessel disease: Insights from a large prospective cohort study. NeuroImage, 2019, 189, 727-733.	4.2	15
143	Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders, 2019, 30, 236-243.	2.0	69
144	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	10.2	110

#	Article	IF	CITATIONS
145	Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension studya~a~ Multiple Sclerosis and Related Disorders, 2019, 33, 131-138.	2.0	15
146	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	9.0	455
147	Accurate, rapid and reliable, fully automated MRI brainstem segmentation for application in multiple sclerosis and neurodegenerative diseases. Human Brain Mapping, 2019, 40, 4091-4104.	3.6	22
148	A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. Multiple Sclerosis Journal, 2019, 25, 1682-1685.	3.0	32
149	Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. Annals of Clinical and Translational Neurology, 2019, 6, 1081-1089.	3.7	43
150	Damage of the lateral geniculate nucleus in MS. Neurology, 2019, 92, e2240-e2249.	1.1	29
151	Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells. Frontiers in Immunology, 2019, 10, 829.	4.8	24
152	Effect of dimethyl fumarate on lymphocytes in RRMS. Neurology, 2019, 92, e1724-e1738.	1.1	66
153	Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology, 2019, 92, e1007-e1015.	1.1	346
154	Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology, 2019, 266, 1182-1193.	3.6	61
155	Hepatitis E virus infections in patients with MS on oral disease-modifying treatment. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e594.	6.0	7
156	PARP-1 deregulation in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731989460.	1.0	10
157	MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry. Brain Imaging and Behavior, 2019, 13, 1361-1374.	2.1	27
158	Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1673-1681.	3.0	9
159	Design and construction of an innovative brain phantom prototype for MRI. Magnetic Resonance in Medicine, 2019, 81, 1165-1171.	3.0	13
160	Unraveling treatment response in multiple sclerosis. Neurology, 2019, 92, 180-192.	1.1	88
161	Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis Journal, 2019, 25, 1915-1925.	3.0	122
162	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 458-468.	1.9	71

#	Article	IF	CITATIONS
163	Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis. JAMA Neurology, 2019, 76, 274.	9.0	56
164	Learning ability correlates with brain atrophy and disability progression in RRMS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 38-43.	1.9	18
165	Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus. Rheumatology, 2019, 58, 908-913.	1.9	19
166	Effect of <i>HLA-DRB1</i> alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. Multiple Sclerosis Journal, 2019, 25, 565-573.	3.0	9
167	Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 678-686.	3.0	148
168	The role of the cerebellum in multiple sclerosis—150 years after Charcot. Neuroscience and Biobehavioral Reviews, 2018, 89, 85-98.	6.1	48
169	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nature Reviews Neurology, 2018, 14, 199-213.	10.1	157
170	Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 777-785.	3.0	46
171	Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. Multiple Sclerosis Journal, 2018, 24, 214-221.	3.0	77
172	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 96-120.	3.0	458
173	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	10.2	4,605
174	Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the <scp>INFORMS</scp> study. Annals of Clinical and Translational Neurology, 2018, 5, 346-356.	3.7	17
175	Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis. Neurology, 2018, 90, e1324-e1332.	1.1	44
176	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876064.	1.0	32
177	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	13.7	684
178	The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. Multiple Sclerosis Journal, 2018, 24, 535-539.	3.0	15
179	Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Multiple Sclerosis Journal, 2018, 24, 963-973.	3.0	79
180	Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis. Journal of Autoimmunity, 2018, 86, 39-50.	6.5	63

#	Article	IF	CITATIONS
181	Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. Multiple Sclerosis Journal, 2018, 24, 1883-1891.	3.0	2
182	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. Multiple Sclerosis Journal, 2018, 24, 1485-1498.	3.0	19
183	Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1605-1616.	3.0	26
184	085â€Clinical outcomes were better for relapsing-remitting multiple sclerosis (RRMS) patients who remained on natalizumab compared to those who switched to oral or injectable therapies after 2 years in the tysabri [®] observational program (TOP). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A34.2-A34.	1.9	0
185	Measuring and Validating the Levels of Brain-Derived Neurotrophic Factor in Human Serum. ENeuro, 2018, 5, ENEURO.0419-17.2018.	1.9	95
186	Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis. European Neurology, 2018, 80, 207-214.	1.4	5
187	Neurofilament light chain serum levels correlate with 10â€year <scp>MRI</scp> outcomes in multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1478-1491.	3.7	115
188	A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression. Journal of Neuroinflammation, 2018, 15, 255.	7.2	20
189	The hippocampus in multiple sclerosis. Lancet Neurology, The, 2018, 17, 918-926.	10.2	90
190	Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology, 2018, 84, 527-536.	5.3	42
191	Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology, 2018, 14, 577-589.	10.1	1,177
192	061â€Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A25.2-A25.	1.9	5
193	Clinical Correlations of Brain Lesion Location in Multiple Sclerosis: Voxel-Based Analysis of a Large Clinical Trial Dataset. Brain Topography, 2018, 31, 886-894.	1.8	22
194	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. Multiple Sclerosis and Related Disorders, 2018, 24, 11-19.	2.0	17
195	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Journal of the Neurological Sciences, 2018, 391, 72-76.	0.6	22
196	Spinal cord volume loss. Neurology, 2018, 91, e349-e358.	1.1	66
197	Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 25, 14-20.	2.0	13
198	Reference videos reduce variability of motor dysfunction assessments in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731879239.	1.0	5

#	Article	IF	CITATIONS
199	Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain, 2018, 141, 2382-2391.	7.6	345
200	Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Multiple Sclerosis Journal, 2017, 23, 253-265.	3.0	126
201	Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study. Multiple Sclerosis Journal, 2017, 23, 597-603.	3.0	66
202	Cocapture of cognate and bystander antigens can activate autoreactive B cells. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 734-739.	7.1	54
203	Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 285-294.	1.9	38
204	Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 1692-1694.	27.0	50
205	Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Annals of Neurology, 2017, 81, 857-870.	5.3	768
206	Sodium intake and multiple sclerosis activity and progression in <scp>BENEFIT</scp> . Annals of Neurology, 2017, 82, 20-29.	5.3	80
207	Evaluation of no evidence of progression or active disease (nepad) in patients with primary progressive multiple sclerosis in the oratorio trial. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.85-e1.	1.9	0
208	No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Multiple Sclerosis Journal, 2017, 23, 1736-1747.	3.0	18
209	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 221-234.	27.0	1,322
210	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 209-220.	27.0	1,324
211	PML risk and natalizumab: the elephant in the room. Lancet Neurology, The, 2017, 16, 864-865.	10.2	3
212	Fluid biomarker and electrophysiological outcome measures for progressive MS trials. Multiple Sclerosis Journal, 2017, 23, 1600-1613.	3.0	28
213	Teriflunomide slows BVL in relapsing MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e390.	6.0	65
214	Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology, 2017, 89, 1584-1593.	1.1	65
215	Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study. NeuroImage, 2017, 163, 106-114.	4.2	27
216	Preliminary results of the opera i and opera ii open-label extension study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.90-e1.	1.9	1

#	Article	IF	CITATIONS
217	Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 17, 32-40.	2.0	9
218	Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS. Multiple Sclerosis Journal, 2017, 23, 656-664.	3.0	34
219	PO114â€Neda achievement by time interval with daclizumab. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A42.1-A42.	1.9	0
220	PO128â€Infusion-related reactions with ocrelizumab in rms and ppms. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A46.1-A46.	1.9	0
221	PO129â€Neda analysis by epoch in the opera studies of ocrelizumab. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A46.2-A46.	1.9	3
222	α4-integrin receptor desaturation and disease activity return after natalizumab cessation. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e388.	6.0	25
223	Laquinimod Safety Profile. International Journal of MS Care, 2017, 19, 16-24.	1.0	15
224	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309690.	1.9	90
225	Individual Assessment of Brain Tissue Changes in MS and the Effect of Focal Lesions on Short-Term Focal Atrophy Development in MS: A Voxel-Guided Morphometry Study. International Journal of Molecular Sciences, 2016, 17, 489.	4.1	11
226	Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP). PLoS ONE, 2016, 11, e0144834.	2.5	8
227	Efficacy and Safety of Fingolimod in an Unselected Patient Population. PLoS ONE, 2016, 11, e0146190.	2.5	18
228	Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2016, 73, 1089.	9.0	92
229	Prognostic factors for long-term outcomes in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731666640.	1.0	11
230	Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. Journal of Neurology, 2016, 263, 1418-1426.	3.6	42
231	Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Multiple Sclerosis and Related Disorders, 2016, 5, 97-104.	2.0	75
232	Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial). Journal of Neurology, 2016, 263, 1364-1374.	3.6	13
233	Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 2016, 6, 102-115.	1.6	33
234	Natalizumab-induced POU2AF1/Spi-B upregulation. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e223.	6.0	27

#	Article	IF	CITATIONS
235	Multiple Sclerosis and Antibodies against KIR4.1. New England Journal of Medicine, 2016, 374, 1496-1498.	27.0	20
236	Neurofilament light chain level is a weak risk factor for the development of MS. Neurology, 2016, 87, 1076-1084.	1.1	85
237	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology, 2016, 87, 978-987.	1.1	109
238	Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, The, 2016, 15, 1148-1159.	10.2	52
239	Mitochondrial cytopathy with common MELAS mutation presenting as multiple system atrophy mimic. Neurology: Genetics, 2016, 2, e121.	1.9	1
240	DACLIZUMAB HYP VS IM INTERFERON BETA-1A IN MS: NEDA RESULTS FROM DECIDE. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.47-e1.	1.9	1
241	Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Multiple Sclerosis and Related Disorders, 2016, 9, 36-46.	2.0	48
242	Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis. Journal of Neurology, 2016, 263, 354-360.	3.6	30
243	Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life – A post hoc analysis of the TEMSO and TOWER studies. Multiple Sclerosis and Related Disorders, 2016, 7, 33-40.	2.0	32
244	Power estimation for non-standardized multisite studies. NeuroImage, 2016, 134, 281-294.	4.2	36
245	Assessing response to interferon-l ² in a multicenter dataset of patients with MS. Neurology, 2016, 87, 134-140.	1.1	98
246	Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731663411.	1.0	10
247	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurology, The, 2016, 15, 292-303.	10.2	679
248	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet, The, 2016, 387, 1075-1084.	13.7	379
249	Monitoring multiple sclerosis by multimodal evoked potentials: Numerically versus ordinally scaled scoring systems. Clinical Neurophysiology, 2016, 127, 1864-1871.	1.5	34
250	Long-term safety and efficacy of teriflunomide. Neurology, 2016, 86, 920-930.	1.1	108
251	Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e215.	6.0	18
252	A comparative analysis of Patient-Reported Expanded Disability Status Scale tools. Multiple Sclerosis Journal, 2016, 22, 1349-1358.	3.0	54

#	Article	IF	CITATIONS
253	Inclusion of brain volume loss in a revised measure of â€~no evidence of disease activity' (NEDA-4) in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1297-1305.	3.0	228
254	Long-term (up to 4.5â€years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 468-475.	1.9	137
255	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis Journal, 2016, 22, 520-532.	3.0	34
256	The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. PLoS ONE, 2016, 11, e0152347.	2.5	38
257	Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. Deutsches Ärzteblatt International, 2016, 113, 879-886.	0.9	14
258	What is new in MS spasticity research? Poster session highlights. Neurodegenerative Disease Management, 2015, 5, 27-30.	2.2	0
259	Comparative efficacy of switching to natalizumab in active multiple sclerosis. Annals of Clinical and Translational Neurology, 2015, 2, 373-387.	3.7	57
260	Cognitive rehabilitation of working memoryÂin juvenile multiple sclerosis–effects on cognitive functioning, functional MRI and network related connectivity. Restorative Neurology and Neuroscience, 2015, 33, 713-725.	0.7	25
261	Case-Based fMRI Analysis after Cognitive Rehabilitation in MS: A Novel Approach. Frontiers in Neurology, 2015, 6, 78.	2.4	24
262	Switching from natalizumab to fingolimod. Neurology, 2015, 85, 29-39.	1.1	110
263	Quantified CSF antibody reactivity against myelin in multiple sclerosis. Annals of Clinical and Translational Neurology, 2015, 2, 1116-1123.	3.7	6
264	Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. Neurology and Therapy, 2015, 4, 93-104.	3.2	80
265	2015 Multiple Sclerosis Experts Summit. Neurodegenerative Disease Management, 2015, 5, 1-2.	2.2	Ο
266	Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e144.	6.0	16
267	Comparison between balanced steady-state free precession and standard spoiled gradient echo magnetization transfer ratio imaging in multiple sclerosis: methodical and clinical considerations. NeuroImage, 2015, 108, 87-94.	4.2	6
268	The role of cerebellar abnormalities in neuromyelitis optica – a comparison with multiple sclerosis and healthy controls. Multiple Sclerosis Journal, 2015, 21, 757-766.	3.0	9
269	Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology, 2015, 84, 872-879.	1.1	137
270	Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology, 2015, 84, 784-793.	1.1	119

#	Article	IF	CITATIONS
271	A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients — A twelve month follow-up. Journal of Neuroimmunology, 2015, 285, 68-70.	2.3	41
272	On the origin of Neurostatus. Multiple Sclerosis and Related Disorders, 2015, 4, 182-185.	2.0	62
273	Optimizing treatment initiation: Effects of a patient education program about fingolimod treatment on knowledge, self-efficacy and patient satisfaction. Multiple Sclerosis and Related Disorders, 2015, 4, 444-450.	2.0	13
274	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process. Nature Reviews Neurology, 2015, 11, 471-482.	10.1	354
275	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain, 2015, 138, 918-931.	7.6	147
276	Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis. Expert Opinion on Drug Safety, 2015, 14, 749-759.	2.4	15
277	Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. Journal of Neuroinflammation, 2015, 12, 46.	7.2	149
278	MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. Lancet Neurology, The, 2015, 14, 443-454.	10.2	105
279	Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology, 2015, 84, 1639-1643.	1.1	153
280	Long-term effects of fingolimod in multiple sclerosis. Neurology, 2015, 84, 1582-1591.	1.1	173
281	Varicella-Zoster Virus Infections in Patients Treated With Fingolimod. JAMA Neurology, 2015, 72, 31.	9.0	142
282	Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis. Journal of Neurology, 2015, 262, 2627-2634.	3.6	16
283	Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. Journal of Neurology, 2015, 262, 2466-2471.	3.6	4
284	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2015, 373, 1418-1428.	27.0	245
285	No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. Neurology, 2015, 85, 1694-1701.	1.1	55
286	Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurology, 2015, 72, 1458.	9.0	130
287	Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1202-1207.	1.9	76
288	EFFECT OF TERIFLUNOMIDE ON LYMPHOCYTE AND NEUTROPHIL COUNTS. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.25-e4.	1.9	0

#	Article	IF	CITATIONS
289	Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis. Journal of Neurology, 2015, 262, 1909-1917.	3.6	18
290	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. Nature Reviews Neurology, 2015, 11, 597-606.	10.1	422
291	Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis–related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. Clinical Therapeutics, 2015, 37, 2543-2551.	2.5	9
292	Nonconventional MRI and microstructural cerebral changes in multiple sclerosis. Nature Reviews Neurology, 2015, 11, 676-686.	10.1	109
293	A phase lla randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. Multiple Sclerosis Journal, 2015, 21, 885-893.	3.0	53
294	Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. Journal of Neurology, 2015, 262, 326-336.	3.6	20
295	Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST). NeuroImage: Clinical, 2015, 7, 43-52.	2.7	23
296	Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 410-418.	1.9	111
297	Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 273-279.	1.9	144
298	Usability and Acceptability of ASSESS MS: Assessment of Motor Dysfunction in Multiple Sclerosis Using Depth-Sensing Computer Vision. JMIR Human Factors, 2015, 2, e11.	2.0	25
299	MS disease activity in RESTORE. Neurology, 2014, 82, 1491-1498.	1.1	166
300	Efficacy of subcutaneous interferon Â-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 647-653.	1.9	23
301	Progression in disability and regional grey matter atrophy in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 202-213.	3.0	30
302	Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. Multiple Sclerosis Journal, 2014, 20, 234-242.	3.0	19
303	Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e28.	6.0	7
304	Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 851-858.	1.9	101
305	Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1190-1197.	1.9	156
306	Labelâ€fusionâ€segmentation and deformationâ€based shape analysis of deep gray matter in multiple sclerosis: The impact of thalamic subnuclei on disability. Human Brain Mapping, 2014, 35, 4193-4203.	3.6	34

#	Article	IF	CITATIONS
307	MiR-126: a novel route for natalizumab action?. Multiple Sclerosis Journal, 2014, 20, 1363-1370.	3.0	36
308	BRAIN VOLUME CHANGE AND DISABILITY IN FINGOLIMOD TRIALS. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.44-e4.	1.9	0
309	Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis Journal, 2014, 20, 51-56.	3.0	38
310	Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis Journal, 2014, 20, 705-716.	3.0	295
311	Lesion-to-ventricle distance and other risk factors for the persistence of newly formed black holes in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 322-330.	3.0	8
312	Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology, 2014, 83, 78-86.	1.1	115
313	Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4 ⁺ T Cells of Patients with Relapsing-Remitting Multiple Sclerosis. Journal of Immunology Research, 2014, 2014, 1-11.	2.2	48
314	Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. Multiple Sclerosis and Related Disorders, 2014, 3, 147-155.	2.0	57
315	Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 294-302.	2.0	37
316	Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurology, The, 2014, 13, 353-363.	10.2	271
317	Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study. Journal of Neurology, 2014, 261, 490-499.	3.6	13
318	Improved Characterization of Visual Evoked Potentials in Multiple Sclerosis by Topographic Analysis. Brain Topography, 2014, 27, 318-327.	1.8	15
319	Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. Journal of Neurology, 2014, 261, 267-276.	3.6	117
320	Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2014, 13, 247-256.	10.2	476
321	MRI characteristics of periaqueductal lesions in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 542-551.	2.0	13
322	Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings. Multiple Sclerosis and Related Disorders, 2014, 3, 494-504.	2.0	105
323	Determinants of iron accumulation in deep grey matter of multiple sclerosis patients. Multiple Sclerosis Journal, 2014, 20, 1692-1698.	3.0	47
324	Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders, 2014, 3, 341-349.	2.0	12

#	Article	IF	CITATIONS
325	Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression. JAMA Neurology, 2014, 71, 306.	9.0	402
326	Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies. Clinical Therapeutics, 2014, 36, 1958-1971.	2.5	36
327	Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. Journal of Neurology, 2014, 261, 2429-2437.	3.6	37
328	Molecular mechanism underlying the impact of vitamin D on disease activity of MS. Annals of Clinical and Translational Neurology, 2014, 1, 605-617.	3.7	44
329	Clinical trials in multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 445-453.	1.8	8
330	First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. Multiple Sclerosis and Related Disorders, 2014, 3, 629-638.	2.0	68
331	The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients. Multiple Sclerosis Journal, 2014, 20, 356-364.	3.0	76
332	Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years. Multiple Sclerosis Journal, 2014, 20, 1348-1354.	3.0	41
333	Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of Neurology, 2014, 261, 1781-1788.	3.6	23
334	Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. Journal of Neurology, 2014, 261, 1794-1802.	3.6	69
335	Multiple sclerosis registries in Europe – results of a systematic survey. Multiple Sclerosis Journal, 2014, 20, 1523-1532.	3.0	58
336	Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2014, 13, 977-986.	10.2	254
337	Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286.	1.1	2,344
338	Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS) Tj ETQq0 0 0 545-556.	rgBT /Ov 10.2	erlock 10 Tf 707
339	Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis Journal, 2014, 20, 243-252.	3.0	51
340	Multicenter mapping in the healthy brain. Magnetic Resonance in Medicine, 2014, 71, 1103-1107.	3.0	17
341	Quantifying Progression of Multiple Sclerosis via Classification of Depth Videos. Lecture Notes in Computer Science, 2014, 17, 429-437.	1.3	23
342	Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial. PLoS ONE, 2014, 9, e86663.	2.5	31

#	Article	IF	CITATIONS
343	Cerebellar Abnormalities Contribute to Disability Including Cognitive Impairment in Multiple Sclerosis. PLoS ONE, 2014, 9, e86916.	2.5	73
344	Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. Journal of Neurology, 2013, 260, 2472-2480.	3.6	35
345	Efficacy and safety of interferon beta-1b sc in older RRMS patients—a posthoc analysis of the BEYOND study. Journal of Neurology, 2013, 260, 1838-1845.	3.6	9
346	Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. Journal of Neurology, 2013, 260, 1388-1395.	3.6	38
347	Glutamate gene polymorphisms predict brain volumes in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 281-288.	3.0	20
348	A comparative study of CSF neurofilament light and heavy chain protein in MS. Multiple Sclerosis Journal, 2013, 19, 1597-1603.	3.0	122
349	Histone deacetylase gene variants predict brain volume changes in multiple sclerosis. Neurobiology of Aging, 2013, 34, 238-247.	3.1	31
350	Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration. European Journal of Radiology, 2013, 82, e848-e852.	2.6	12
351	Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis. JAMA Neurology, 2013, 70, 1017.	9.0	37
352	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study. Journal of Neurology, 2013, 260, 2297-2305.	3.6	62
353	Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurology, The, 2013, 12, 756-767.	10.2	205
354	Balance control in multiple sclerosis: Correlations of trunk sway during stance and gait tests with disease severity. Gait and Posture, 2013, 37, 55-60.	1.4	51
355	Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Multiple Sclerosis Journal, 2013, 19, 1310-1319.	3.0	69
356	Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1290-1296.	3.0	103
357	Detection of Cerebrospinal Fluid Leaks by Intrathecal Contrast-Enhanced Magnetic Resonance Myelography. JAMA Neurology, 2013, 70, 1576-7.	9.0	3
358	Rapamycin Attenuates the Progression of Tau Pathology in P301S Tau Transgenic Mice. PLoS ONE, 2013, 8, e62459.	2.5	196
359	Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases. PLoS ONE, 2013, 8, e75091.	2.5	375
360	Preserved Antigen-Specific Immune Response in Patients with Multiple Sclerosis Responding to IFNÎ ² -Therapy. PLoS ONE, 2013, 8, e78532.	2.5	39

#	Article	IF	CITATIONS
361	Relevance of Spinal Cord Abnormalities to Clinical Disability in Multiple Sclerosis: MR Imaging Findings in a Large Cohort of Patients. Radiology, 2013, 269, 542-552.	7.3	52
362	Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Multiple Sclerosis Journal, 2012, 18, 181-195.	3.0	33
363	Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1625-1632.	3.0	75
364	Evaluating the Potential Benefit of Interferon Treatment in Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2012, 308, 290.	7.4	14
365	Teriflunomide for oral therapy in multiple sclerosis. Expert Review of Clinical Pharmacology, 2012, 5, 617-628.	3.1	18
366	Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1466-1471.	3.0	58
367	Spatiotemporal distribution of white matter lesions in relapsing–remitting and secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1577-1584.	3.0	26
368	Alemtuzumab for multiple sclerosis: who and when to treat?. Lancet, The, 2012, 380, 1795-1797.	13.7	6
369	Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial. Journal of Neurology, 2012, 259, 2401-2413.	3.6	37
370	Evaluation of a new approach for semi-automatic segmentation of the cerebellum in patients with multiple sclerosis. Journal of Neurology, 2012, 259, 2673-2680.	3.6	27
371	3D GRASE arterial spin labelling reveals an inverse correlation of cortical perfusion with the white matter lesion volume in MS. Multiple Sclerosis Journal, 2012, 18, 1570-1576.	3.0	29
372	Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Multiple Sclerosis Journal, 2012, 18, 143-152.	3.0	220
373	Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study. Multiple Sclerosis Journal, 2012, 18, 314-321.	3.0	63
374	Combined evoked potentials as markers and predictors of disability in early multiple sclerosis. Clinical Neurophysiology, 2012, 123, 406-410.	1.5	52
375	Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis. Archives of Neurology, 2012, 69, 1259.	4.5	97
376	Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis. CNS Drugs, 2012, 26, 11-37.	5.9	36
377	Reporting of subgroup analyses from clinical trials – Author's reply. Lancet Neurology, The, 2012, 11, 747-748.	10.2	2
378	Multivariate pattern classification of gray matter pathology in multiple sclerosis. NeuroImage, 2012, 60, 400-408.	4.2	47

#	Article	IF	CITATIONS
379	Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2012, 367, 1098-1107.	27.0	1,493
380	Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis. New England Journal of Medicine, 2012, 366, 1000-1009.	27.0	329
381	Biplanar MRI for the assessment of the spinal cord in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1560-1569.	3.0	82
382	Longitudinal gray matter changes in multiple sclerosis—Differential scanner and overall diseaseâ€related effects. Human Brain Mapping, 2012, 33, 1225-1245.	3.6	40
383	Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology, 2012, 259, 898-905.	3.6	66
384	Evolution of MS lesions to black holes under DNA vaccine treatment. Journal of Neurology, 2012, 259, 1375-1382.	3.6	15
385	Screening for balance disorders in mildly affected multiple sclerosis patients. Journal of Neurology, 2012, 259, 1413-1419.	3.6	32
386	Altered microRNA expression in B lymphocytes in multiple sclerosis. Clinical Immunology, 2012, 144, 70-79.	3.2	111
387	Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurology, The, 2012, 11, 33-41.	10.2	185
388	Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurology, The, 2012, 11, 420-428.	10.2	152
389	Facial nerve palsy and anti-Ku autoantibodies. Journal of Neurology, 2012, 259, 361-363.	3.6	3
390	Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Therapeutic Advances in Neurological Disorders, 2011, 4, 3-14.	3.5	45
391	Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet, The, 2011, 378, 1779-1787.	13.7	636
392	Mannose-Binding Lectin Deficiency Is Associated With Smaller Infarction Size and Favorable Outcome in Ischemic Stroke Patients. PLoS ONE, 2011, 6, e21338.	2.5	77
393	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurology, The, 2011, 10, 520-529.	10.2	204
394	Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurology, The, 2011, 10, 745-758.	10.2	247
395	Fingolimod for Multiple Sclerosis: Mechanism of Action, Clinical Outcomes, and Future Directions. Current Neurology and Neuroscience Reports, 2011, 11, 492-497.	4.2	54
396	Antigenâ€specific adaptive immune responses in fingolimodâ€treated multiple sclerosis patients. Annals of Neurology, 2011, 69, 408-413.	5.3	78

#	Article	IF	CITATIONS
397	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology, 2011, 69, 292-302.	5.3	8,001
398	Altered functional adaptation to attention and working memory tasks with increasing complexity in relapsingâ€remitting multiple sclerosis patients. Human Brain Mapping, 2011, 32, 1704-1719.	3.6	33
399	Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Multiple Sclerosis Journal, 2011, 17, 1098-1106.	3.0	167
400	Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2011, 365, 1293-1303.	27.0	842
401	Genome-wide Association Study in a High-Risk Isolate for Multiple Sclerosis Reveals Associated Variants in STAT3 Gene. American Journal of Human Genetics, 2010, 86, 285-291.	6.2	210
402	A confusing patient's history: small or large vessel vasculitis?. Rheumatology International, 2010, 30, 1681-1683.	3.0	1
403	A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. Journal of Neuroimmunology, 2010, 220, 114-119.	2.3	80
404	Effect of immunomodulatory medication on regional gray matter loss in relapsing–remitting multiple sclerosis—A longitudinal MRI study. Brain Research, 2010, 1325, 174-182.	2.2	31
405	Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsingâ€remitting multiple sclerosis. Human Brain Mapping, 2010, 31, 1542-1555.	3.6	42
406	Altered expression of miRâ€17â€5p in CD4 ⁺ lymphocytes of relapsing–remitting multiple sclerosis patients. European Journal of Immunology, 2010, 40, 888-898.	2.9	191
407	Evidence for acute neurotoxicity after chemotherapy. Annals of Neurology, 2010, 68, 806-815.	5.3	51
408	Learning from Nature: Pregnancy Changes the Expression of Inflammation-Related Genes in Patients with Multiple Sclerosis. PLoS ONE, 2010, 5, e8962.	2.5	69
409	Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2010, 362, 402-415.	27.0	1,983
410	Dissociation of Voluntary and Emotional Innervation after Stroke. New England Journal of Medicine, 2010, 363, e25.	27.0	7
411	Prognostic Value of Copeptin. Stroke, 2010, 41, 1564-1567.	2.0	86
412	Midregional Pro-Atrial Natriuretic Peptide and Outcome in Patients With Acute Ischemic Stroke. Journal of the American College of Cardiology, 2010, 56, 1045-1053.	2.8	75
413	Dimethyl fumarate for multiple sclerosis. Expert Opinion on Investigational Drugs, 2010, 19, 1603-1612.	4.1	51
414	A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2010, 362, 387-401.	27.0	2,314

#	Article	IF	CITATIONS
415	Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Human Molecular Genetics, 2009, 18, 2078-2090.	2.9	371
416	Age-Dependent B Cell Autoimmunity to a Myelin Surface Antigen in Pediatric Multiple Sclerosis. Journal of Immunology, 2009, 183, 4067-4076.	0.8	182
417	Magnetic Resonance Imaging Predictors of Conversion to Multiple Sclerosis in the BENEFIT Study. Archives of Neurology, 2009, 66, 1345-52.	4.5	32
418	250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology, The, 2009, 8, 889-897.	10.2	377
419	Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurology, The, 2009, 8, 987-997.	10.2	322
420	Abnormal connectivity of the sensorimotor network in patients with MS: A multicenter fMRI study. Human Brain Mapping, 2009, 30, 2412-2425.	3.6	51
421	The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. Journal of Neurology, 2009, 256, 405-415.	3.6	193
422	Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nature Genetics, 2009, 41, 776-782.	21.4	729
423	Working memory training in patients with multiple sclerosis – comparison of two different training schedules. Restorative Neurology and Neuroscience, 2009, 27, 225-235.	0.7	109
424	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Human Molecular Genetics, 2009, 18, 767-778.	2.9	419
425	Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis — A longitudinal voxel-based morphometry study. NeuroImage, 2009, 45, 60-67.	4.2	83
426	Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b. Journal of Neurology, 2008, 255, 480-487.	3.6	63
427	Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. Journal of Neuroimmunology, 2008, 194, 153-164.	2.3	100
428	Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet, The, 2008, 372, 1463-1472.	13.7	457
429	Non-communicating syringomyelia: a feature of spinal cord involvement in multiple sclerosis. Brain, 2008, 131, 1776-1782.	7.6	18
430	Natalizumab: Targeting α ₄ -Integrins in Multiple Sclerosis. Neurodegenerative Diseases, 2008, 5, 16-22.	1.4	147
431	Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. Journal of International Medical Research, 2008, 36, 204-8; author reply 208-10.	1.0	3
432	Magnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study. Archives of Neurology, 2007, 64, 1292.	4.5	46

#	Article	IF	CITATIONS
433	Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet, The, 2007, 370, 389-397.	13.7	468
434	Treating clinically isolated syndromes suggestive of MS – Authors' reply. Lancet, The, 2007, 370, 2000-2001.	13.7	0
435	Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis. New England Journal of Medicine, 2007, 356, 371-378.	27.0	236
436	Healthâ€related quality of life in multiple sclerosis: effects of natalizumab. Annals of Neurology, 2007, 62, 335-346.	5.3	172
437	Anti-interferon-β neutralising activity is not entirely mediated by antibodies. Journal of Neuroimmunology, 2007, 192, 198-205.	2.3	22
438	Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurology, The, 2007, 6, 431-441.	10.2	331
439	Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. Journal of Neurology, 2007, 254, 160-168.	3.6	52
440	Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. Journal of Neurology, 2007, 254, 597-604.	3.6	25
441	Neutralising antibodies to interferon β in multiple sclerosis. Journal of Neurology, 2007, 254, 827-837.	3.6	48
442	Mental health problems in children of somatically ill parents, e.g. multiple sclerosis. European Child and Adolescent Psychiatry, 2007, 16, 199-207.	4.7	35
443	Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2006, 355, 1124-1140.	27.0	996
444	A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2006, 354, 899-910.	27.0	2,916
445	Retraining attention in MS. Journal of the Neurological Sciences, 2006, 245, 147-151.	0.6	23
446	Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurology, The, 2006, 5, 343-354.	10.2	246
447	Transcriptional profiling of multiple sclerosis: towards improved diagnosis and treatment. Expert Review of Molecular Diagnostics, 2006, 6, 843-855.	3.1	11
448	Optimizing brain MRI protocols in the follow-up of patients with multiple sclerosis. Magnetic Resonance Imaging, 2005, 23, 469-474.	1.8	3
449	Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria― Annals of Neurology, 2005, 58, 840-846.	5.3	4,495
450	The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosis. Journal of Neurology, 2005, 252, 1455-1458.	3.6	23

#	Article	IF	CITATIONS
451	10 years of interferon beta-1b (Betaferon \hat{A}^{\otimes}) therapy. Journal of Neurology, 2005, 252, iii1-iii2.	3.6	10
452	Genomics and proteomics: role in the management of multiple sclerosis. Journal of Neurology, 2005, 252, iii21-iii27.	3.6	7
453	Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. Multiple Sclerosis Journal, 2005, 11, 227-231.	3.0	33
454	Interferons in multiple sclerosis. Neurologic Clinics, 2005, 23, 189-214.	1.8	7
455	Oculopharyngeal muscular dystrophy - an under-diagnosed disorder?. Swiss Medical Weekly, 2005, 135, 574-86.	1.6	38
456	Neutralizing antibodies against IFN-Â in multiple sclerosis: antagonization of IFN-Â mediated suppression of MMPs. Brain, 2004, 127, 259-268.	7.6	63
457	Multiple sclerosis as a generalized CNS disease—comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS. Journal of Neuroimmunology, 2004, 152, 154-167.	2.3	101
458	Cervical dystonia as first manifestation of multiple sclerosis. Journal of Neurology, 2004, 251, 1408-1410.	3.6	20
459	European validation of a standardized clinical description of multiple sclerosis. Journal of Neurology, 2004, 251, 1472-1480.	3.6	40
460	New aspects in the treatment of multiple sclerosis with interferon beta-1b. Journal of Neurology, 2004, 251, iv1.	3.6	1
461	Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?. Journal of Neurology, 2004, 251, v57-v64.	3.6	13
462	Analysis of Impairment Related Functional Architecture in MS Patients during Performance of Different Attention Tasks. Journal of Neurology, 2003, 250, 461-472.	3.6	155
463	Interferon-beta antibodies: implications for the treatment of MS. Lancet Neurology, The, 2003, 2, 528.	10.2	17
464	Immune-mediated neuropathies: etiology and pathogenic relationship to aging processes. Journal of Neuroimmunology, 2003, 137, 1-11.	2.3	16
465	Endonasal Surgery for Contact Point Headaches: A 10-Year Longitudinal Study. Laryngoscope, 2003, 113, 2151-2156.	2.0	64
466	Competing interests in multiple sclerosis research. Lancet, The, 2003, 361, 350-351.	13.7	17
467	Extraocular Blood Flow and Endothelin-1 Plasma Levels in Patients with Multiple Sclerosis. European Neurology, 2003, 49, 164-168.	1.4	90
468	Atrophy Is Detectable Within a 3-Month Period in Untreated Patients With Active Relapsing Remitting Multiple Sclerosis. Archives of Neurology, 2003, 60, 1736.	4.5	45

#	Article	IF	CITATIONS
469	The Janus face of CNS-directed autoimmune response: a therapeutic challenge. Brain, 2002, 125, 2379-2380.	7.6	7
470	INTERLEUKIN 15 STIMULATES PRODUCTION OF MATRIX METALLOPROTEINASE-9 AND TISSUE INHIBITOR OF METALLOPROTEINASE-1 BY HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS. Cytokine, 2001, 13, 244-247.	3.2	27
471	Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Research Reviews, 2001, 36, 249-257.	9.0	236
472	The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain, 2001, 124, 1743-1753.	7.6	151
473	Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: Application of an extended blood-brain barrier leakage correction. Journal of Magnetic Resonance Imaging, 2000, 11, 495-505.	3.4	88
474	Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nature Medicine, 2000, 6, 1176-1182.	30.7	506
475	The αβ T Cell Response to Self-Glycolipids Shows a Novel Mechanism of CD1b Loading and a Requirement for Complex Oligosaccharides. Immunity, 2000, 13, 255-264.	14.3	144
476	Self glycolipids as T-cell autoantigens. European Journal of Immunology, 1999, 29, 1667-1675.	2.9	256
477	Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet, The, 1999, 353, 964-969.	13.7	476
478	Self glycolipids as T-cell autoantigens. , 1999, 29, 1667.		2
479	Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet, The, 1998, 352, 1491-1497.	13.7	961
480	Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. Journal of Neurology, 1997, 244, 76-84.	3.6	70
481	Combinations of drugs. Multiple Sclerosis Journal, 1996, 1, 400-403.	3.0	6
482	Fatal vascular leak syndrome with extensive hemorrhage, peripheral neuropathy and reactive erythrophagocytosis: an unusual complication of recombinant IL-3 therapy. Leukemia and Lymphoma, 1996, 20, 337-340.	1.3	18
483	Proton MRS of Gadolinium-enhancing MS Plaques and Metabolic Changes in Normal-Appearing White Matter. Magnetic Resonance in Medicine, 1995, 33, 811-817.	3.0	54
484	T cell receptor γδrepertoire is skewed in cerebrospinal fluid of multiple sclerosis patients: molecular and functional analyses of antigen-reactive γδclones. European Journal of Immunology, 1995, 25, 355-363.	2.9	40
485	Expression of the B cell-associated tyrosine kinase gene Lyn in primary neuroblastoma tumours and its modulation during the differentiation of neuroblastoma cell lines. Biochemical and Biophysical Research Communications, 1992, 186, 1403-1409.	2.1	4
486	Development of multiple sclerosis in patient on long-term sulfasalazine. Lancet, The, 1990, 335, 409-410.	13.7	14

#	Article	IF	CITATIONS
487	Clinical trials of immunosuppression and immunomodulation in multiple sclerosis. Journal of Neuroimmunology, 1988, 20, 261-268.	2.3	7
488	An attempt to quantify magnetic resonance imaging in multiple sclerosis — correlation with clinical parameters. Neurosurgical Review, 1987, 10, 133-135.	2.4	11